PL4233867T3 - Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego - Google Patents
Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowegoInfo
- Publication number
- PL4233867T3 PL4233867T3 PL22158443.6T PL22158443T PL4233867T3 PL 4233867 T3 PL4233867 T3 PL 4233867T3 PL 22158443 T PL22158443 T PL 22158443T PL 4233867 T3 PL4233867 T3 PL 4233867T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- optic neuropathy
- pde5 inhibitor
- ischemic optic
- anterior ischemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22158443.6A EP4233867B1 (en) | 2022-02-24 | 2022-02-24 | Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4233867T3 true PL4233867T3 (pl) | 2026-02-09 |
Family
ID=80787134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22158443.6T PL4233867T3 (pl) | 2022-02-24 | 2022-02-24 | Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250170131A1 (pl) |
| EP (1) | EP4233867B1 (pl) |
| JP (1) | JP2025505847A (pl) |
| CN (1) | CN118742309A (pl) |
| CA (1) | CA3244595A1 (pl) |
| ES (1) | ES3045971T3 (pl) |
| PL (1) | PL4233867T3 (pl) |
| TW (1) | TW202342046A (pl) |
| WO (1) | WO2023161314A1 (pl) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4828670B2 (ja) | 1996-10-28 | 2011-11-30 | 千寿製薬株式会社 | 眼循環障害改善剤 |
| IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
| AU779991B2 (en) * | 1999-08-10 | 2005-02-24 | Board Of Regents, The University Of Texas System | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
| WO2001041756A2 (en) | 1999-12-02 | 2001-06-14 | University Of South Florida | Method and composition for treatment of ischemic neuronal reperfusion injury |
| US20020168424A1 (en) | 2002-07-31 | 2002-11-14 | Dr. Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma |
| US10159669B2 (en) | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| EP3833395A1 (en) | 2018-08-06 | 2021-06-16 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
| EP4100014B1 (en) | 2020-02-05 | 2024-01-03 | Nicox S.A. | Compositions for the treatment of glaucoma and ocular hypertension |
| WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
-
2022
- 2022-02-24 EP EP22158443.6A patent/EP4233867B1/en active Active
- 2022-02-24 ES ES22158443T patent/ES3045971T3/es active Active
- 2022-02-24 PL PL22158443.6T patent/PL4233867T3/pl unknown
-
2023
- 2023-02-23 TW TW112106578A patent/TW202342046A/zh unknown
- 2023-02-23 WO PCT/EP2023/054494 patent/WO2023161314A1/en not_active Ceased
- 2023-02-23 CA CA3244595A patent/CA3244595A1/en active Pending
- 2023-02-23 US US18/841,347 patent/US20250170131A1/en active Pending
- 2023-02-23 CN CN202380023170.9A patent/CN118742309A/zh active Pending
- 2023-02-23 JP JP2024549642A patent/JP2025505847A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118742309A (zh) | 2024-10-01 |
| TW202342046A (zh) | 2023-11-01 |
| ES3045971T3 (en) | 2025-12-01 |
| JP2025505847A (ja) | 2025-02-28 |
| EP4233867A1 (en) | 2023-08-30 |
| CA3244595A1 (en) | 2023-08-31 |
| WO2023161314A1 (en) | 2023-08-31 |
| US20250170131A1 (en) | 2025-05-29 |
| EP4233867C0 (en) | 2025-09-03 |
| EP4233867B1 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220807A1 (es) | Nuevos inhibidores de egfr | |
| MX2021001952A (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met. | |
| SMT202300467T1 (it) | Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso | |
| JOP20190076B1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| ECSP18083443A (es) | Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| MX2021014175A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| IL307883A (en) | HDAC6 inhibitors for use in the treatment of dilated myocardial disease | |
| MX2021010115A (es) | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. | |
| PT3972603T (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| GB202416046D0 (en) | Compounds of use in methods for the treatment or prohylaxis of a coronavirus infection or covid 19 | |
| MX2022004027A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida. | |
| IL321393A (en) | CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency | |
| EA202191984A1 (ru) | Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза | |
| PL4233867T3 (pl) | Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego | |
| PT4084778T (pt) | Formulações de inibidores de quinase amorfas e métodos de utilização das mesmas | |
| GB201918413D0 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| PH12021551590A1 (en) | Quinoline compounds as inhibitors of tam and met kinases | |
| EP4193995A4 (en) | USE OF BTK INHIBITORS TO TREAT DISEASES | |
| PL4482481T3 (pl) | Związki do zastosowania w leczeniu dystrofinopatii | |
| ZA202206439B (en) | Use of phosphodiesterase 5 inhibitor in preparation of medicament for resisting fibrotic diseases | |
| AU2023902805A0 (en) | Combination for use in the treatment of glioma | |
| HK40079284A (en) | Agents for use in the treatment of tissue damage | |
| GB202111866D0 (en) | Prodrugs for use in the treatment of tissue damage | |
| HK40079285A (en) | Agents for use in the treatment of tissue damage 2 |